| | |
| | |
| Clinical data | |
|---|---|
| Trade names | Equioxx, Previcox |
| AHFS/Drugs.com | |
| License data | |
| Routes of administration | By mouth |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H20O5S |
| Molar mass | 336.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Firocoxib, sold under the brand names Equioxx and Previcox among others, is a nonsteroidal anti-inflammatory drug of the COX-2 inhibitor (coxib) class, approved for use in horses (Equioxx) and for use in dogs (Previcox). [2] [4] [9] Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. [10] Firocoxib is not intended or approved for use in human medicine. [2] [4] [5] [6] [11]
Firocoxib, manufactured by Merial, was approved for veterinary use in the United States for dogs in July 2004, [12] and for horses in July 2007, as an oral paste (Equioxx) and July 2016, as tablets. [13] [14]
Firocoxib is also available as a generic medication for horses [14] and for dogs. [12]